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PROBLEM 
  More preteens and teens could be receiving the HPV vaccine 
  Guidelines recommend ages 9 – 26 
  At TCHC, there were largely 2 camps of unvaccinated children I saw: 
  Those whose parents held personal beliefs about the vaccines or the immune system 
  Those who had not yet been educated on HPV or the vaccine 
  Most patients I saw in their 20s had started the vaccine 
  The majority of preteens and teens I saw had not received the HPV vaccine 
  It may be too late to wait until patients can decide for themselves 
  The parents that are lacking education should be identified and receive it 
  It may be impossible to change some patient’s personal beliefs 
COST & BURDEN IN U.S. 
  Cost of HPV infection for both men and women [1] 
  Estimated lifetime total cost ages 15–24 y.o. = $2.9 billion 
  Treatment of anogenital warts in all age groups in year 2000 = $167.4 million 
  Only HIV is more expensive in terms of STI 
  Cost of annual cervical screening and treatment for HPV-related disease [2] 
  Estimated avg. $26,415 per 1000 women 
  Ages 20 – 29 avg. $51, 863 per 1000 women due to higher prevalence 
  Estimated $3.4 billion annually 
  90% of cost attributed to strategies for prevention 
  Treatment of precancerous lesions 
  Routine paps and guideline recommendations 
  10% of cost due to treatment of cancer 
COMMUNITY PERSPECTIVE 
  MA, 18F, patient at TCHC 
  Currently 8 months pregnant and unvaccinated against HPV 
  Did not get vaccine because she is afraid of needles 
  Was not aware that HPV could cause cancer or how common it is 
  Willing to receive vaccine after receiving educational information 
  May already be too late for MA given she is already sexually active 
 
  IW, 16F, patient at TCHC 
  Currently unvaccinated 
  Mother does not want vaccine because she believes “body can fight the infection” 
  Interestingly she requested a flu vaccine 
  IW stated “I’m not of legal age to be sexually active” 
  When counseled alone and provided educational information, Ivy changed her mind 
  We still need to convince Ivy’s mother 
INTERVENTION 
  Target under-educated population with patient handout 
  Under-educated = does not know about complications of HPV infection 
  Educate all patients ages 9 – 26 and their parents 
  Specifically address in lay terms 3 main areas: 
  Define what HPV is 
  Describe what HPV can cause 
  Explain why the HPV vaccine is recommended for children 
  Provide additional sources of information 
RESPONSE 
  The most common reason for declining vaccine after receiving 
educational information was due to a parent’s personal beliefs 
  Among unvaccinated patients who were unaware of HPV complications, 
most were willing to receive vaccine after receiving educational 
information 
  Most preteens and teens were willing to receive vaccine when 
counseled alone, but they always deferred to the parent’s decision 
  Parent’s personal beliefs against vaccines were wide ranging: 
  “lack of safety data” 
  “body can fight the infection” 
  “not sexually active yet” 
EFFECTIVENESS & LIMITATIONS 
  The intervention was effective in the population of patients that had not 
been informed of the potential complications of HPV infection 
  The intervention was not effective when a parent declined due to 
personal beliefs against the vaccine 
  The results were limited by a small sample size: 
  TCHC is not primarily a pediatric clinic 
  The length of the intervention thus far has only been 5 weeks 
  The intervention is also challenged by the fact that decision making 
capacity is deferred to parents in most of the target patients 
RECOMMENDATIONS 
  Really focus on targeting parents with education when children reach 
the age of 9, which is current recommended guideline 
  Most persuasive point = increased efficacy when given at younger age 
  The intervention is effective in the right population 
  Identify those who have not received educational information 
  Assume everyone is under-educated until they are vaccinated 
  It may be impossible to change some patient’s personal beliefs 
  Provide these patients with educational information and support their decision 
  Unfortunately some patients are at risk due to their parent’s decisions 
  Counsel these patients alone at every visit and provide educational information 
  Given time patients whose parents decline may request on their own 
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